Searched for
NOVO NORDISK 2025 OUTLOOK
FMCG, healthcare in line for strong show in FY27: BrickworksIndia's consumer goods and healthcare sectors are poised for robust growth this fiscal year, driven by tax relief, increasing consumer spen...- Titan expects gold prices to stay elevated, volatile amid global tensionsTitan anticipates elevated and volatile gold prices due to global geopolitical tensions, impacting short-term jewellery demand. However, th...
- Consumer & healthcare best placed most sectors stable, says BrickworkIndia's consumer goods and healthcare sectors are poised for strong growth this fiscal year, fueled by tax cuts, rising consumer demand, an...
- Microsoft launches firm to help companies adopt AI with $2.5 billionMicrosoft has launched a new venture, Microsoft Frontier Company, backed by $2.5 billion, to guide businesses in selecting and integrating ...
- Medical device maker Zimmer Biomet to hire 500 employees in 3 years for tech centre in IndiaMedical device giant Zimmer Biomet is set to significantly expand its Indian footprint by hiring 500 professionals over three years for its...
- Shantha Biologics to Make Injectable Drug Cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
- Growth engine revving as GST, auto sales rise despite global roadblocksIndia's economy shows robust growth in Q1 FY27, with GST collections soaring 13.9% to Rs 1.95 lakh crore in June. Car sales surged 24%, and...
- Solvency buffers at insurers thinning; general insurance sector more of a concernThe Reserve Bank of India's latest report highlights concerns over thinning capital in the insurance sector. While life insurers remain com...
- Oyo parent files updated DRHP for Rs 6,650 crore IPO: Key things to knowOyo's parent company, Prism, has filed for a Rs 6,650 crore IPO, with plans for a potential pre-IPO placement. The bulk of the funds will b...
- Oyo parent Prism files updated IPO papers for fresh issue worth Rs 6,650 croreOYO parent Prism, formerly Oravel Stays, has filed an updated DRHP with SEBI for a Rs 6,650 crore IPO entirely through fresh issue. Proceed...
- PRISM files IPO papers for Rs 6650 crore fresh issue, reports Rs 748 crore profit in 9MFY26Oyo's parent company, PRISM, has filed its IPO papers with SEBI, planning a Rs 6,650 crore fresh issue to repay borrowings. The hospitality...
- Waaree Energies shares crash 5%. Can this US ruling dent solar panel maker's image for long?Waaree Energies shares fell nearly 5% after a US Customs ruling triggered concerns over reputational impact despite the company’s clarifica...
- Prestige Group holds Rs 65,000 crore unrecognised revenue in books on record pre-sales: Chairman Irfan RazackPrestige Estates Projects Ltd holds a substantial Rs 65,000 crore in unrecognised revenue, fueled by robust housing sales. The company repo...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Bombay HC cancels 'Duphachrit' trademark, rules it deceptively similar to Abbott's 'Dupha' familyThe Bombay High Court has cancelled Thane-based Menschlich Healthcare's trademark 'Duphachrit' in favour of Abbott Product Operations AG. T...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- Novo Nordisk hit by cyber incident, probes data breachDanish drugmaker Novo Nordisk has confirmed a security incident. Unauthorised access to internal IT systems occurred. Certain non-public da...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
Load More
